Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Investigators Highlight Top Advances at ESMO 2022

November 7th 2022

Data presented at the ESMO Congress 2022 highlighted advances across treatment modalities, including landmark data for trials in melanoma, breast cancer, and lung cancer, as well as early data that made headlines in a subgroup of patients with colon cancer.

KEYNOTE-189 Analysis Supports Pembrolizumab/Chemo as a Frontline Standard in Metastatic NSCLC

November 4th 2022

Five-year follow-up data from the phase 3 KEYNOTE-189 trial further confirms the use of first-line pembrolizumab in combination with pemetrexed and platinum improves long-term survival outcomes for patients with treatment-naïve, metastatic, nonsquamous non–small cell lung cancer.

The Evolving Treatment Landscape in Relapsed/ Refractory Follicular Lymphoma

November 4th 2022

On September 8, 2022, OncLive® brought together physicians who treat FL to participate in a virtual workshop and discuss the treatment landscape and management of patients with relapsed/refractory (R/R) FL. The discussion was led by Krish Patel, MD; perspectives and insights on current treatment options, trial data, and other novel therapies were exchanged.

Exploring the Role of Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

November 4th 2022

ON SEPTEMBER 11, 2022, OncLive® brought together medical oncologists who specialize in the treatment of non–small cell lung cancer (NSCLC). Moderated by Grace K. Dy, MD, the objectives of the workshop were to evaluate the potential role and impact of new antibody-drug conjugates (ADCs) in the treatment of patients with NSCLC.

Targeted Therapies and Expanded NGS Access Improve Decision Making in Lung Cancer

November 3rd 2022

Melissa L. Johnson, MD, shares key insights from the meeting, including pertinent findings in KRAS G12C¬–mutated NSCLC from the phase 3 CodeBreak 200 study and positive findings with atezolizumab in platinum-ineligible patients with NSCLC.

SRF388 Monotherapy Generates Responses in Locally Advanced/Metastatic NSCLC

November 3rd 2022

SRF388 elicited responses in pretreated patients with locally advanced or metastatic non–small cell lung cancer.

NSCLC Molecular Testing Recommendations for Community Hospitals

November 2nd 2022

Recommendations for community hospitals and physicians on the critically necessary molecular tests needed for patients with NSCLC.

Adjuvant Therapy in EGFR-Mutated NSCLC

November 2nd 2022

Drs Spicer and Sabari explain if and when they test patients with NSCLC for EGFR mutations after surgical resection.

POSEIDON Study of Dual Immunotherapy Regimens in Advanced NSCLC

November 2nd 2022

Melissa Johnson, MD, explains the design and outcomes of the multi-arm POSEIDON study, which featured a combination of 4 agents for the treatment of advanced NSCLC.

EMPOWER LUNG-3 Study of Chemoimmunotherapy in Advanced NSCLC

November 2nd 2022

Key opinion leaders discuss data from the EMPOWER-Lung-3 study investigating the use of cemiplimab plus chemotherapy in both squamous and non-squamous NSCLC.

Dr. Johnson on the Effect of the IPSOS Trial on Treatment in Platinum-Ineligible NSCLC

November 2nd 2022

Melissa L. Johnson, MD, discusses the paradigm-shifting results of the phase 3 IPSOS trial of atezolizumab in patients with metastatic non–small cell lung cancer.

Receiving Molecular Testing Results for NSCLC

November 2nd 2022

Bhuvana Ramkumar, MD, and Neil Morganstein, MD, share if they believe there should be a standard for molecular testing reports, and how frequently they communicate with their patients during the process.

Integrating Molecular Testing Results into Electronic Medical Records

November 2nd 2022

The panel reflects on challenges with the EMR, and the impact it has on treatment decision making for their patients with NSCLC.

Lorlatinib Improves PFS, Reduces CNS Progression in Advanced ALK+ NSCLC

November 2nd 2022

Lorlatinib improved progression-free survival and reduced 12-month cumulative incidence of central nervous system progression compared with crizotinib in patients with advanced ALK-positive non–small cell lung cancer irrespective of brain metastases at baseline.

Telisotuzumab Vedotin Plus Erlotinib Shows Encouraging Activity in Advanced c-Met+ NSCLC

November 1st 2022

Telisotuzumab vedotin in combination with erlotinib induced promising outcomes in patients with advanced, EGFR-mutated, c-MET-positive non–small cell lung cancer who were contraindicated for surgery or other approved therapies.

Thoracic Experts Review ESMO 2022 Data in NSCLC

October 31st 2022

In a special OncLive video program, The Board, D. Ross Camidge, MD, PhD, led a discussion regarding key abstracts that were presented during the 2022 ESMO Congress in non–small cell lung cancer.

Sunvozertinib Showcases Early Safety, Efficacy in EGFR Exon 20–Mutated NSCLC

October 30th 2022

D. Ross Camidge, MD, PhD, discusses the potential utility of sunvozertinib in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations, the efficacy and safety data observed with the agent, and future research directions.

NVL-520 Demonstrates Preliminary Clinical Activity in ROS1-Positive NSCLC

October 28th 2022

The novel brain-penetrant ROS1-selective inhibitor NVL-520 elicited clinical activity and was well tolerated in heavily pretreated patients with ROS1 fusion–positive non–small cell lung cancer.

Taletrectinib Shows Promising ORR and Tolerability in ROS1+ NSCLC

October 26th 2022

Misako Nagasaka, MD, PhD, discusses the various needs taletrectinib meets in the ROS1-positive population, initial efficacy data with the agent, and its impressive safety profile.

KEYNOTE-407 Study of Frontline Pembrolizumab and Chemotherapy in Advanced NSCLC

October 26th 2022

Dr Velcheti reviews data on the chemoimmunotherapy treatment of squamous NSCLC from the KEYNOTE-407 study.